Det bliver endog rigtigt spændende at se, hvad der sker af udmeldinger i morgen. Troldmanden har fortalt at regnskab kommer inden åbning. Men det er CC, der er vigtigt, iøvrigt både for neuro og gen.
Jeg er tilmeldt til kl 14 og lytter som sindssyg :
Welcome to GlaxoSmithKline's Q4 Results 2008 Webcast
The Live webcast will commence at 14:00 GMT, Thursday 5th February 2009.
The webcast includes access to video and synchronised slides of the presentation.
Welcome to GlaxoSmithKline's Q4 Results 2008 Webcast
The Live webcast will commence at 14:00 GMT, Thursday 5th February 2009.
The webcast includes access to video and synchronised slides of the presentation.
har jeg nu tilføjet et gsk nyhedsfeed inde under nyheder. Det kan I nu tilføje og så sidde og vente på takeover meddelelsen indenfor 6 måneder. Hvis nogen er i tvivl om hvordan I gør det så skriv.
Eller er der noget stort på vej?? Sådan at CC overtager regnskabet, virker mærkeligt
Summary
• EPS before major restructuring -9% CER, up 6% in sterling terms
- excluding previously announced Q4 legal charge of £278 million, 2008 EPS 109.3p -6%
CER as expected
- net cash inflow from operating activities £7.3 billion up 19% in sterling terms
• Early progress to globalise and diversify
- Emerging Markets sales up 12% in 2008; 4 transactions executed
- vaccines sales £2.5 billion up 15% aided by Cervarix and Rotarix
- consumer brand acquisitions, including Biotene; EU approval of alli in January 2009
• Sustained pipeline progress from discovery to approval:
- 12 products launched in 2008, including Promacta, Tyverb, Rotarix and Kinrix
- 17% of FDA approvals for NCEs and new vaccines in 2008
- US filing of pazopanib and phase III start for Syncria announced today
- more than 10 key products currently filed with regulators worldwide
- 30 assets in late-stage development
- 70 internal and external drug discovery engines
• Existing restructuring programme expanded
- pre-tax annual savings increased from £0.7 billion to £1.7 billion by 2011
- pre-tax charges increased from £1.5 billion to £3.6 billion
- savings in 2009 mitigate expected decline to gross margin due to product mix changes
and support further investment behind strategic priorities
Outlook
Andrew Witty, CEO said: “2008 marked a turning point for GSK and those factors which
impacted our performance, in particular declines in Avandia sales, are now starting to
reduce. 2008 also saw the first steps towards a radical transformation of our business
model. We enter 2009 with confidence and expect to make further good progress in
implementing our strategic priorities that will enable us to meet our long-term objective of
reducing risk and delivering sustainable growth to shareholders.”
• EPS before major restructuring -9% CER, up 6% in sterling terms
- excluding previously announced Q4 legal charge of £278 million, 2008 EPS 109.3p -6%
CER as expected
- net cash inflow from operating activities £7.3 billion up 19% in sterling terms
• Early progress to globalise and diversify
- Emerging Markets sales up 12% in 2008; 4 transactions executed
- vaccines sales £2.5 billion up 15% aided by Cervarix and Rotarix
- consumer brand acquisitions, including Biotene; EU approval of alli in January 2009
• Sustained pipeline progress from discovery to approval:
- 12 products launched in 2008, including Promacta, Tyverb, Rotarix and Kinrix
- 17% of FDA approvals for NCEs and new vaccines in 2008
- US filing of pazopanib and phase III start for Syncria announced today
- more than 10 key products currently filed with regulators worldwide
- 30 assets in late-stage development
- 70 internal and external drug discovery engines
• Existing restructuring programme expanded
- pre-tax annual savings increased from £0.7 billion to £1.7 billion by 2011
- pre-tax charges increased from £1.5 billion to £3.6 billion
- savings in 2009 mitigate expected decline to gross margin due to product mix changes
and support further investment behind strategic priorities
Outlook
Andrew Witty, CEO said: “2008 marked a turning point for GSK and those factors which
impacted our performance, in particular declines in Avandia sales, are now starting to
reduce. 2008 also saw the first steps towards a radical transformation of our business
model. We enter 2009 with confidence and expect to make further good progress in
implementing our strategic priorities that will enable us to meet our long-term objective of
reducing risk and delivering sustainable growth to shareholders.”
It is also worth noting that GSK secured 17% of FDA approvals for new NCEs and vaccines,
last year. In an environment where declining R&D productivity for pharmaceutical companies
is of increasing concern, I believe that this level of innovation is very promising. This ‘share’ of
FDA approvals is also more than double our share of the US market.
last year. In an environment where declining R&D productivity for pharmaceutical companies
is of increasing concern, I believe that this level of innovation is very promising. This ‘share’ of
FDA approvals is also more than double our share of the US market.
ja og 5,7 milliarder pund i cash and cash equivalents.
